BC Innovations | Dec 12, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease MicroRNA-33a (miR-33a); miR-33b Mouse and primate studies suggest an 8mer anti-miRNA that targets both miR-33a and miR-33b could...
BC Innovations | Dec 12, 2013
Tools & Techniques

Family seeds

It has been long assumed that the specificity of microRNA inhibitors is determined by length-dogma held that anti-miRNAs should be more than 16 nucleotides and approximate the length of the actual miRNA targets. Now, an...
BC Innovations | Oct 27, 2011
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis MicroRNA-33a (miR-33a); miR-33b Primate studies suggest antagonizing miR-33a and miR-33b could help treat atherosclerosis. In African green monkeys, an antisense miRNA inhibiting both...
BC Week In Review | Apr 4, 2011
Company News

Regulus, New York University deal

Regulus received exclusive rights to the university's IP covering methods of use in modulating microRNA-33a (miR-33a) and microRNA-33b (miR-33b) for metabolic diseases. Regulus is developing several candidates that target miRNAs including an oligonucleotide that targets...
Items per page:
1 - 4 of 4